FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema

FDA Approves Kalbitor for Treating Potentially Life-Threatening Attacks of Hereditary Angioedema
Wed, 02 Dec 2009 15:45:00 -0600

The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420